文献速递神经介入DSA

Neuroform Atlas支架治疗颅内动脉瘤的安全性与有效性:系统评价、Meta分析与Meta回归

Safety and Efficacy of the Neuroform Atlas Stent for Treatment of Intracranial Aneurysms: A Systematic Review, Meta-Analysis, and Meta-Regression.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-06-03

该系统评价与Meta分析纳入42项研究共2434例颅内动脉瘤患者,评估Neuroform Atlas支架治疗的安全性与有效性。最终随访Raymond-Roy分级1级或2级闭塞率达95%,1级为82%,不良事件发生率均≤5%,mRS 0分为93%。作者认为该支架闭塞率高、不良事件少,但结论的普适性有限。

要点

  • NAS治疗颅内动脉瘤最终RROC 1/2级闭塞率达95%,其中RROC 1级82%。
  • 术后mRS 0分者占93%,全部不良事件发生率均≤5%。
  • 作者认为NAS对破裂与未破裂动脉瘤均高效安全,但结论普适性有限。

核心结论

  • 作者认为NAS治疗颅内动脉瘤高度有效,闭塞率高且不良事件发生率低。
  • 作者指出该支架在破裂与未破裂动脉瘤中均体现安全性与有效性,但结论的普适性有限。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、EMBASE、Cochrane Central Register of Controlled Trials及clinicaltrials.gov,自建库至2024年6月。
  • 纳入42项研究共2434例患者,平均年龄51至73岁,覆盖实验性研究、观察性研究与病例系列,含破裂与未破裂动脉瘤及各年龄组。
  • 以Raymond-Roy分级(RROC)评估动脉瘤闭塞率,同时记录mRS与支架相关不良事件。
  • 统计分析使用R 4.3.2的meta与metasens包,结果以比例及相应CI报告,并行Meta回归、留一法与敏感性分析。

诊断标准与关键数值

  • 最终随访RROC 1级或2级闭塞率95%,RROC 1级82%,RROC 2级12%,RROC 3级5%。
  • mRS 0分93%、1分5%、2分3%、3分2%、4分0%、5分0%、6分1%。
  • 全部不良事件发生率均≤5%。

临床应用与阅片要点

  • 作者认为NAS治疗颅内动脉瘤高效且不良事件少,可用于破裂与未破裂动脉瘤的管理。
  • 原文未据此给出具体阅片或报告流程推荐。

局限性

  • 因病因特异性数据有限,无法分析支架置入相关的死亡与并发症。
  • 尽管纳入研究数量大,比较性研究仍 scarce(原文写作 scarce)。
  • 作者指出其结论的普适性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Intracranial aneurysms (IAs) are the major cause of subarachnoid hemorrhage. Stent-assisted coiling, especially with the Neuroform Atlas stent (NAS), has proved more effective than coiling alone for treating these aneurysms.

PURPOSE: To perform a systematic review and meta-analysis to investigate the efficacy and safety of the NAS in treating IAs.

DATA SOURCES: A comprehensive literature search was conducted on PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and clinicaltrials.gov from inception until June 2024.

STUDY SELECTION: We included studies on ruptured and unruptured IAs treated with the NAS, covering experimental, observational, and case series across all age groups. The aneurysm occlusion rate was assessed by using the Raymond-Roy classification (RROC). The mRS and adverse events related to stent use were also recorded.

DATA ANALYSIS: The statistical analysis was conducted on R Version 4.3.2 by using the packages "meta" and "metasens." We reported our results as proportions with their corresponding CIs. Meta-regression, leave-one-out, and sensitivity analyses were conducted to confirm the robustness of our results.

DATA SYNTHESIS: A total of 42 studies including 2434 participants with a mean age of 51 to 73 years were included. Among angiographic outcomes, the final RROC 1/RROC 2 was achieved in 95% of the patients, final RROC 1 in 82%, RROC 2 in 12%, and RROC 3 in 5% of the patients. Additionally, 93% of the patients showed mRS grade 0, 5% showed mRS grade 1, 3% showed mRS grade 2, 2% showed mRS grade 3, 0% showed mRS grade 4, 0% showed mRS grade 5, and 1% showed mRS grade 6. All adverse events had a ≤5% rate.

LIMITATIONS: Due to limited cause-specific data, we were unable to analyze mortality specific to the stent placement and complications. Despite the large number of studies included, comparative studies were still observed to be scarce.

CONCLUSIONS: Although the generalizability of our findings is limited, this study demonstrates that the NAS is highly effective for treating IAs, with high occlusion rates and a low incidence of adverse events. The stent's performance, supported by comprehensive analysis, highlights its safety and efficacy in managing both ruptured and unruptured aneurysms.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Akram U, Ahmed S, Nadeem ZA, et al. Safety and Efficacy of the Neuroform Atlas Stent for Treatment of Intracranial Aneurysms: A Systematic Review, Meta-Analysis, and Meta-Regression. AJNR Am J Neuroradiol. 2025. PMID: 39578103. doi:10.3174/ajnr.A8593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。